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Introduction: Intracoronary (IC) papaverine which is one of the commonly used agents for
Fractional Flow Reserve (FFR) estimation has been reported to cause transient ST elevation
in some patients. This phenomenon has not been systematically studied.
Material and methods: This is a prospective, observational study. Consecutive patients, who
underwent FFR at our institute using IC papaverine from May 2012 to April 2013, were
included. FFR was done when clinically indicated. The procedure involved administration
of 20 mg papaverine (Paparin e Troikaa, Ahmedabad) as a fast bolus by intracoronary
route followed by a 10 cc contrast flush, following which pressure measurements were
made. Continuous ECG recording by Philips Hemodynamic Laboratory was obtained for all
patients throughout the procedure. Post procedure, they were observed for any delayed
effects and eventual outcome was documented. Fischer’s mid-p test was used for statistical
analysis.
Result: Twenty-five patients (18 males, 7 females, mean age 57.9  20 years) underwent FFR
using Papaverine. The mean LVEF was (51  15%). Fourteen patients (56%) developed
transient ST elevation 0.5 mm in one or more leads which resolved spontaneously in all
cases without any sequelae. The presence of a significant lesion either in the coronary
artery being evaluated or in a remote coronary artery did not predict the ST elevation.
70.5% of diabetics (p ¼ 0.02), 75% of hypertensives (p ¼ 0.008) and 75% of patients with LVH
(p ¼ 0.008) had ST elevation. None of the 5 patients without any one of these comorbidities
showed ST elevation.
Conclusion: Transient ST elevation occurs in a significant proportion of cases receiving IC
papaverine which is not associated with any adverse clinical outcomes. Micro vascular
dysfunction is the most likely mechanism of this phenomenon.
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Fractional Flow Reserve (FFR) is an established method of
assessing the significance of borderline coronary lesions, thus
giving incremental information beyond coronary
angiography.1e7 Themethod of estimating FFR entails passing
a Doppler wire into the coronary artery under study and
crossing the lesionunder evaluationwith the transducer of the
wire. This is followed by induction of maximum hyperemia
using one of several agents e intracoronary (IC) adenosine, IC
papaverine, ICnicorandil, intravenous (IV) adenosine infusion,
and IV dobutamine infusion. FFR is then derived as the ratio of
pressure distal to the lesion (Pd), to the mean aortic pressure
(Pa). A ratio of less than 0.80 denotes significant stenosis.
3,4,8e12
In 1986, IC papaverine was proposed as the agent of choice
for determination of FFR by Wilson and White due to its
several advantages. An ideal hyperemic agent should have
rapid onset of action, produce sustained true maximum hy-
peremia with a single injection, be of low cost, should have
reasonably short duration of action and no or minimal side
effects. Papaverine produces true steady-state hyperemia
with a single IC injection, unlike adenosine which needs IV
infusion to produce steady-state hyperemia. This permits
evaluation of serial lesions and repeated measurements with
a single injection. Papaverine can be used in patients with
asthma and obstructive lung disease and irrespective of usage
of theophyllines. The cost of papaverine is low compared to IV
adenosine infusion or IC nicorandil. The duration of hyper-
emia of papaverine is 3 min, which is long enough for pull-
back measurements but short enough to perform fresh mea-
surements. Side effects reported during use of IC papaverine
include polymorphic ventricular tachycardia, ventricular
fibrillation and QTc prolongation, which are potentially
serious, but are rare and usually self-terminating.13e15
Anecdotal reports of transient ST elevation with the
administration of IC papaverine have been documented in
literature; however a systematic study of this phenomenon
has not been attempted.16,17Table 1e Patient characteristics. Total number of patients
(n)[ 25
S. no. Characteristic Number
1. Male/Female 18/7
2. Age (mean) 57.9  20 years
3. Hypertension 16 (64%)
4. Diabetes Mellitus 17 (68%)
5. LVH 16 (64%)
6. LV EF 42  15%
7. Remote significant lesion 15 (60%)2. Material and methods
This is a prospective observational study undertaken in our
institution from May 2012 to April 2013. In this period, 25 pa-
tientswith intermediate coronary lesionsunderwent clinically
indicated FFR using IC papaverine as the hyperemic agent.
The FFR Doppler wire (Volcano Prime, Rancho Cordova, CA,
USA)was introduced into the coronaryarteryunder evaluation
andnegotiated across the lesion using fluoroscopy guidance in
the cath lab. The Volcano Prime IVUS/FFR system (Rancho
Cordova,CA,USA)wasused for carryingout the FFRprocedure.
ECGwas recordedby six lead PhilipsHemodynamic Laboratory
(Royal Phillips Electronics, Netherlands). We monitored the
three standard limb leads and the three augmented limb leads.
In all cases, readings were taken using IC papaverine
(20 mg e Paparin e Troikaa, Ahmedabad, India) as a bolus
injection followed by a 10 cc contrast flush. There was
continuous monitoring of ECG and intra arterial blood pres-
sure throughout the procedure.3. Definitions
1. ST elevation: Elevation of ST segment of 0.5 mm in any
one lead.
2. LVH was diagnosed on echocardiography using the Amer-
ican Society of Echocardiography’s guidelines.
3. LV dysfunction was defined as significant if LVEF 45% on
echocardiography by Simpson’s method.
4. Remote lesionwas defined as a lesion in a vessel other than
the vessel subjected to FFR.
5. Significant lesion was defined as a lesion which was
assessed to have a severity 70% by angiography. Signifi-
cant lesion by FFR was defined as a FFR value less than 0.8.4. Statistics
The categorical variables we derived were analyzed using the
Fisher’s mid-P test to calculate the statistical significance of
the differences between the patient populations. Values of
p < 0.05 were considered significant.5. Results
A total of 25 patients underwent FFR using papaverine IC in
the period from 7th May 2012 to 1st May 2013. Their baseline
characteristics are summarized in Table 1. Fourteen (56%)
developed transient ST segment elevation after intracoronary
injection of papaverine (Fig. 1). None of these cases had
associated chest discomfort, fall in blood pressure or
arrhythmia. The ST elevation lasted for a mean period of 10 s
(range: 5 se30 s) and in all cases resolved spontaneously
(Fig. 2). Coronary check-shoots were taken and iatrogenic
complications like dissection were ruled out.
We attempted to assess the influence of various factors on
the occurrence of this phenomenon of transient ST elevation
(Table 2). The presence of a significant lesion either in the
coronary artery being evaluated or in a remote coronary artery
did not predict the ST elevation. Interestingly the phenome-
non was more often seen in the presence of diabetes, hyper-
tension or LVH. All 14 patients who developed ST elevation
had at least one of these comorbidities, and 10 of these pa-
tients had all the three comorbidities. In contrast, none of the
five patients who did not have these comorbidities exhibited
this phenomenon.
Fig. 1 e 63 years male, hypertensive, diabetic, with LVH, had borderline lesion in mid LAD & mild lesions in LCX and RCA.
FFR of LAD was 0.84. Patient developed ST elevation in 5 leads, almost immediately after IC Papaverine.
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Papaverine (1-[(3,4-dimethoxyphenyl)methyl]-6,-7-dimethoxyi-
soquinoline) is a crystalline alkaloid derived from opium.18 It
results in predictable and sustained coronary vasodilatation.
Side effects reported for papaverine IC include ventricular
tachycardia, ventricular fibrillation requiring defibrillation
and QTc prolongation.13e15
It seems intuitively paradoxical to find IC papaverine
inducing ST elevation as this drug has been used to resolve ST
elevation in patients with vasospastic angina.19 Mahomed
et al first reported ST elevation following injection ofFig. 2 e In the same patient shown in Fig. 1, ST elevapapaverine in a single patient.16 Inoue et al, in Japan, have
reported 4 cases.17
Coronary micro vascular dysfunction is a well recognized
patho physiological entity which is known to cause ischemia
and result in cardiovascular adverse events even in the pres-
ence of angiographically normal epicardial arteries.20e22 It is
well established that diabetes, hypertension or LVH constitute
major risk factors for coronary micro vascular dysfunction.
Our data shows statistically significant association between
these risk factors and the transient ST elevation that we have
observedwith the administration of papaverine. It leads to the
inference that hyperemia caused by papaverine in these pa-
tients with disease in the micro vascular coronary bed resultstion resolved spontaneously in all leads in 10 s.
Table 2 e Results.
S. no. Characteristic Number of patients Phenomenon of transient ST elevation p value
1 Significant
Lesion (by FFR)
13 8 (61.5%) 0.3
2 Non-significant
lesion (by FFR)
12 6 (50%) 0.3
3 Diabetes 17 12 (70.5%) 0.02
4 Hypertension 16 12 (75%) 0.008
5 Tobacco use 4 2 (50%) 0.12
6 LVH 16 12 (75%) 0.008
7 LV dysfunction 4 1 (25%) 0.12
8 Remote significant lesion 15 8 (53.3%) 0.38
9 Total 25 14 (56%)
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deviations. As these effects are transient and reversible, there
are no adverse clinical consequences. This hypothesis is
strengthened by the fact that all of the 14 patients in whom ST
elevation was observed, had one or more of these risk factors
for micro vascular dysfunction. Papaverine appears to un-
mask micro vascular angina in patients with otherwise
normal coronary angiogram andmay provide us an easier on-
table method of diagnosing micro vascular dysfunction than
coronary flow reserve (CFR).
It was earlier proposed that papaverine may induce a steal
phenomenon in the diseased coronary artery by causing
maximum hyperemia in all coronaries, thus leading to the ST
changes.16 We however, did not find any association of this
phenomenon with the presence of significant coronary le-
sions, making this explanation unlikely. In fact, when Gudi-
pati et al demonstrated coronary steal by coronary flow
reserve measurement caused by papaverine after IC injection
into a vessel supplying collaterals to a vessel with chronic
total occlusion, their patient had angina during the period of
ischemia and ST depression rather than elevation.21
We observed that ST elevation was present in all six
monitored leads in themajority of patients. This suggests that
the phenomenon is global rather than local. We did not
observe any reciprocal ST segment depression in any of our
patients associated with ST elevation. These observations
render the hypothesis of ischemia unlikely.
Papaverine has been shown to block rapid and ultrarapid
delayed rectifier Kþ channels.22 It has also been demonstrated
to stimulate Ca2þ induced Kþ channels.23 The complex inter-
play of these actions may conceivably alter cardiac repolari-
zation and result in transient ST elevation. However, no
evidence for this hypothesis exists.7. Limitations
Our study involves a small number of patients and is a purely
an observational study. It nevertheless provides amechanistic
insight to this phenomenon.8. Conclusion
IC papaverine can result in transient ST elevation in some
patients. This phenomenon occurs in more than half of allpatients who receive IC papaverine. The mechanism of this
phenomenon ismost probably due to coronarymicro vascular
dysfunction. The phenomenon is not associated with any
adverse clinical consequences.Conflicts of interest
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